10x Genomics Files 8-K on Financials
Ticker: TXG · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: TXG
TL;DR
10x Genomics dropped an 8-K on Feb 12th about their financials - check it for updates.
AI Summary
On February 12, 2025, 10x Genomics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates that 10x Genomics is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.
Key Players & Entities
- 10x Genomics, Inc. (company) — Registrant
- February 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39035 (identifier) — SEC File Number
- 45-5614458 (identifier) — IRS Employer Identification No.
- 6230 Stoneridge Mall Road, Pleasanton, California 94588 (address) — Registrant's principal executive offices
- (925) 401-7300 (phone_number) — Registrant's principal executive offices telephone number
FAQ
What specific financial information is being reported in this 8-K filing?
The provided excerpt indicates the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail specific financial figures.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated February 12, 2025.
What is the state of incorporation for 10x Genomics, Inc.?
10x Genomics, Inc. is incorporated in Delaware.
What is the SEC file number for 10x Genomics, Inc.?
The SEC file number for 10x Genomics, Inc. is 001-39035.
Where are the principal executive offices of 10x Genomics, Inc. located?
The principal executive offices of 10x Genomics, Inc. are located at 6230 Stoneridge Mall Road, Pleasanton, California 94588.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-02-12 16:10:24
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
Filing Documents
- txg-20250212.htm (8-K) — 27KB
- txg-fy2024earningsreleasee.htm (EX-99.1) — 179KB
- a10x_logoxhorizontalxfullca.jpg (GRAPHIC) — 152KB
- txg-20250212_g1.jpg (GRAPHIC) — 223KB
- 0001770787-25-000011.txt ( ) — 1056KB
- txg-20250212.xsd (EX-101.SCH) — 2KB
- txg-20250212_lab.xml (EX-101.LAB) — 21KB
- txg-20250212_pre.xml (EX-101.PRE) — 12KB
- txg-20250212_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 12, 2025, 10x Genomics, Inc. (the "Company") issued a press release announcing the Company's financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibits 99.1 Press Release dated February 12, 2025.
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: February 12, 2025